Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease

Circulation

Volumn 107, Issue 11, 2003, Pages 1514-1519

  Sin, Don D ^a,b,c   Paul Man, S F ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b INSTITUTE OF HEALTH ECONOMICS   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

C reactive protein; Chronic obstructive pulmonary disease; Epidemiology; Inflammation, systemic

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; AUTACOID; C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ELECTROCARDIOGRAM; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART INJURY; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SCORING SYSTEM; SPIROMETRY; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 0037465734     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000056767.69054.B3     Document Type: Article

References (33)

1. Schunemann HJ, Dorn J, Grant BJ, et al. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest. 2000;118:656-664.
2. Bang KM, Gergen PJ, Kramer R, et al. The effect of pulmonary impairment on all-cause mortality in a national cohort. Chest. 1993;103:536-540.
3. Hole DJ, Watt GC, Davey-Smith G, et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ. 1996;313:711-715.
4. Friedman GD, Klatsky AL, Siegelaub AB. Lung function and risk of myocardial infarction and sudden cardiac death. N Engl J Med. 1976;294:1071-1075.
5. Engstrom G, Lind P, Hedblad B, et al. Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation. 2002;106:2555-2560.
6. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
7. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321:199-204.
8. Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med. 1999;130:933-937.
9. Lagrand WK, Visser CA, Hermens WT. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation. 1999;100:96-102.
10. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 2001;103:1194-1197.
11. National Center for Health Statistics. Plan and Operation of the Third National Health And Nutrition Examination Survey, 1988-94. Hyattsville, Md: US Dept of Health and Human Services; 1994. Publication No. (PHS)94-1308.
12. American Thoracic Society. Standardization of spirometry: 1987 update. Am Rev Respir Dis. 1987;136:1285-1298.
13. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256-1276.
14. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159:179-187.
15. US Department of Health and Human Services (DHHS), National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988-1994: NHANES III Second Laboratory Data File [CD-ROM, Series 11, No. 2A]. Hyattsville, Md: Centers for Disease Control and Prevention; 1998.
16. Rautaharju PM, Warren JW, Jain U, et al. Cardiac infarction injury score: an electrocardiographic coding scheme for ischemic heart disease. Circulation. 1981;64:249-256.
17. Rautaharju PM, MacInnis PJ, Warren JW, et al. Methodology of ECG interpretation in the Dalhousie program: NOVACODE ECG classification procedures for clinical trials and population health surveys. Methods Inf Med. 1990;29:362-374.
18. Gunter EW, Lewis BG, Koncikowski. Laboratory Procedures Used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988-94. Hyattsville, Md: National Center for Health Statistics; 1996.
19. Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131-2135.
20. Wener MH, Mannik M. Rheumatoid factors. In: Rose NR, Conway de Macario E, Fahey JL, et al, eds. Manual of Clinical Laboratory Immunology. 5th ed. Washington, DC: American Society for Microbiology; 1997.
21. Schlesselman S. Case-Control Studies. New York, NY: Oxford; 1982:203-206.
22. Leuraud K, Benichou J. A comparison of several methods to test for the existence of a monotonic dose-response relationship in clinical and epidemiological studies. Stat Med. 2001;20:3335-3351.
23. Schols AM, Creutzberg EC, Buurman WA, et al. Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:1220-1226.
24. Takabatake N, Nakamura H, Abe S, et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1179-1184.
25. Eid AA, Ionescu AA, Nixon LS, et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1414-1418.
26. Schols AM, Buurman WA, Staal van den Brekel AJ, et al. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax. 1996;51:819-824.
27. Cirillo DJ, Agrawal Y, Cassano PA. Lipids and pulmonary function in the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 2002;155:842-848.
28. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165-2168.
29. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477-1482.
30. Buffon A, Biasucci LM, Liuzzo G, et al. Widespread coronary inflammation in unstable angina. N Engl J Med. 2002;347:5-12.
31. Heindl S, Lehnert M, Criee C, et al. Marked sympathetic activation in patients with chronic respiratory failure. Am J Respir Crit Care Med. 2001;164:597-601.
32. Volk T, Schmutzler M, Engelhardt L, et al. Influence of aminosteroid and glucocorticoid treatment on inflammation and immune function during cardiopulmonary bypass. Crit Care Med. 2001;29:2137-2142.
33. Laakko T, Fraker P. Rapid changes in the lymphopoietic and granulopoietic compartments of the marrow caused by stress levels of corticosterone. Immunology. 2002;105:111-119.